Supplemental material
Journal of Medical Economics
Volume 25, 2022 - Issue 1
Open access
2,619
Views
2
CrossRef citations to date
0
Altmetric
Cardiovascular
Cost-utility and cost-benefit analysis of TAVR availability in the US severe symptomatic aortic stenosis patient population
J. P. Sevillaa Life Sciences Group, Data for Decisions, LLC, Waltham, MA, USACorrespondence[email protected]
, Jessica M. Klustya Life Sciences Group, Data for Decisions, LLC, Waltham, MA, USA
https://orcid.org/0000-0003-2665-7935
Younghwan Songb Department of Economics, Union College, Schenectady, NY, USA
, Mark J. Russoc Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA
, Christin A. Thompsond Edwards Lifesciences, Irvine, CA, USA
https://orcid.org/0000-0002-4713-4730
Xiayu Jiaod Edwards Lifesciences, Irvine, CA, USA
, Seth J. Clancyd Edwards Lifesciences, Irvine, CA, USA
& David E. Bloome Department of Global Health and Population, Harvard T. H. Chan School of Public Health, Boston, MA, USA
show all
Pages 1051-1060
|
Received 02 Jun 2022, Accepted 09 Aug 2022, Published online: 25 Aug 2022
Related Research Data
Cost-utility and cost-benefit analysis of TAVR availability in the US severe symptomatic aortic stenosis patient population
Source:
Taylor & Francis
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.